Bob Ang

Bob Ang

Directeur/Bestuurslid bij KOLON TISSUEGENE, INC.

Vermogen: 179 141 $ op 31-07-2026

51 jaar
Health Technology
Finance
Commercial Services

Profiel

Currently, Bob Ang is Director at Alliance for Regenerative Medicine since 2022 and Independent Director at Kolon TissueGene, Inc. Formerly, Dr. Ang was President, CEO, CFO, Director & CAO at Vor Biopharma, Inc. from 2019 to 2025; Director at Enara Bio Ltd.; Senior Associate at Frazier Management LLC from 2008 to 2009; Senior Vice President-Business Development at Bavarian Nordic, Inc. and Bavarian Nordic A from 2013 to 2015; Principal at The Boston Consulting Group, Inc. from 2000 to 2003; Vice President-Medical Affairs at Mallinckrodt Hospital Products, Inc.; Principal at Embark Healthcare; and Chief Business Officer at BioNTech US, Inc. from 2015 to 2019.
Education includes an MBA from Columbia Business School and a doctorate from The University of Western Australia conferred in 1998.

Bekende belangen in openbare bedrijven

OndernemingDatumAantal aandelenTotale waardeWaarderingsdatum
15-04-2026 8.470 ( 0,02% ) 179 141 $ 31-07-2026

Actieve functies van Bob Ang

BedrijvenFunctieBegin
KOLON TISSUEGENE, INC. Directeur/Bestuurslid -
Directeur/Bestuurslid 01-01-2022

Eerdere bekende functies van Bob Ang

BedrijvenFunctieEinde
VOR BIOPHARMA INC. Algemeen Directeur 25-06-2025
NEON THERAPEUTICS, INC. Corporate Officer/Principal 01-08-2019
Corporate Officer/Principal 01-01-2015
BAVARIAN NORDIC A/S Corporate Officer/Principal 01-01-2015
Private Equity Analist 01-10-2009
Ervaring van Bob Ang in detail bekijken

Opleiding van Bob Ang

Ervaring
Beklede functies

Actief

Inactief

Beursgenoteerde bedrijven

Bedrijven in privébezit

Connecties

74

Eerstegraads connecties

13

Bedrijven verbonden in de eerste graad

Man

Vrouw

Besturend

Uitvoerend

Verwante bedrijven

Bedrijven in privébezit13

Finance

Commercial Services

Health Technology

Commercial Services

Health Technology

Health Technology

Consumer Services

Finance

Health Services

Consumer Services

Health Technology

Health Technology

Health Technology